Sienna Cancer Diagnostics Limited announced that Matthew Hoskin will be stepping down from his role as Chief Executive Officer of the Company, and will be replaced by Carl Stubbings, currently a non-executive Director. Carl Stubbings will take up the role of CEO with immediate effect. Carl has been a non-executive Director of Sienna since 2011. Carl is a highly experienced senior leader in the biotechnology and diagnostics industries, with a focus on commercialisation, sales, marketing and business development. His most recent role was as CEO of BCAL, a private company developing a breast cancer diagnostic. He has also recently served as Commercialisation Lead at Minomic, which has commercialised a prostate cancer diagnostic, and a non-executive Director of ASX­listed Analytica. He was previously the Vice President of Sales and Marketing at Focus Diagnostics Inc. and Chief Business Officer at Benitec Biopharma.